Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.

Cell transplantation - 1 Jan 2024

Chang Yu-Hsun, Wu Kun-Chi, Wang Kai-Hung, Ding Dah-Ching

Abstract excerpt

This study aimed to explore the role of ovarian cancer patient-derived organoids (PDOs) in their replicating genetic characteristics and testing drug responsiveness. Ovarian cancer PDOs were cultured in Matrigel with a specialized medium. The successful rate and proliferation rate were calculated. Morphology, histology, and immunohistochemistry (IHC) (PAX8, P53, and WT1) were used to identify the tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ARID1A gene

Share to PAX8 gene

Share to WT1 gene

Share to Mutation

Share to Organoids

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39323050
DOI: 10.1177/09636897241281869
PMCID: PMC11425734

Genes

ARID1A
BRCA1
PAX8
PIK3CA
TP53
WT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.PMID 39323050Read ↗

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testingSemantic proximity Read ↗

Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug ResponsesSemantic proximity Read ↗

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoidsSemantic proximity Read ↗

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoidsSemantic proximity Read ↗

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read ↗

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read ↗

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read ↗

Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current OpportunitiesSemantic proximity Read ↗

Organoid Models Established from Primary Tumors and Patient-Derived Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer PatientsSemantic proximity Read ↗

Exploration of organoids in ovarian cancer: From basic research to clinical translationSemantic proximity Read ↗

Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment.Semantic proximity Read ↗

Patient‐derived organoid culture in epithelial ovarian cancers—Techniques, applications, and future perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.